Two Sigma Investments, LP Lipocine Inc. Transaction History

Two Sigma Investments, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.3 - $0.58 $10,591 - $20,476	-35,304 Reduced 12.2%	253,977 $81,000
Q4 2022 Feb 14, 2023	SELL	$0.37 - $8.65 $13,274 - $310,344	-35,878 Reduced 11.03%	289,281 $115,000
Q3 2022 Nov 14, 2022	SELL	$0.49 - $7.65 $65,424 - $1.02 Million	-133,519 Reduced 29.11%	325,159 $146,000
Q2 2022 Aug 15, 2022	BUY	$0.73 - $1.34 $71,983 - $132,134	98,608 Added 27.39%	458,678 $367,000
Q1 2022 May 16, 2022	BUY	$0.89 - $1.85 $229,148 - $476,319	257,470 Added 250.95%	360,070 $493,000
Q4 2021 Feb 14, 2022	BUY	$0.99 - $1.2 $101,574 - $123,120	102,600 New	102,600 $102,000
Q3 2020 Nov 16, 2020	SELL	$1.21 - $2.23 $117,249 - $216,087	-96,900 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$0.42 - $1.26 $40,698 - $122,094	96,900 New	96,900 $122,000
Q2 2019 Aug 14, 2019	SELL	$1.43 - $2.32 $20,915 - $33,932	-14,626 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$1.46 - $2.33 $21,353 - $34,078	14,626 New	14,626 $34,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $418M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.